5 Things To Know About Ocrevus Dosage
The multiple sclerosis community is buzzing with news of the recent FDA approval of the drug Ocrevus (ocrelizumab) which can be used in the treatment of relapsing-remitting multiple sclerosis (RRMS) and is the first approved drug for the treatment of primary-progressive multiple sclerosis (PPMS).
But how is the drug taken? Here are five important things to know about the dosage and administration of Ocrevus according to everydayhealth.com.
How is it administered?
The first dosage of Ocrevus is delivered via two intravenous infusions, which are taken two weeks apart. Patients will then have further IV infusions every six months.
What is the dosage?
In the clinical trials for the drug, PPMS patients were given 300mg of Ocrevus at each infusion (600mg a month).
Where is it given?
Ocrevus should be given to patients in a clinical setting by a healthcare professional so that patients can be monitored for any adverse reactions.
Are there risks of overdosing?
Because the drug is administered by a healthcare professional and patients are monitored for an hour following the infusion, the risks of overdosing on Ocrevus are negligible. However, if you suspect you have overdosed then you should contact the emergency services immediately.
If you miss a dose due to illness or an unforeseen circumstance, you will need to contact your doctor for further instructions.
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.